AVANIR Pharmaceuticals Hires Matthew R. Ruth as Vice President of Sales
01 Marzo 2006 - 3:15PM
Business Wire
AVANIR Pharmaceuticals (AMEX:AVN.R) announced today that Matthew R.
Ruth has joined the company in the newly created role of Vice
President of Sales. Mr. Ruth will be responsible for building,
training and directing Avanir's sales organization. Prior to
joining AVANIR, Mr. Ruth was the Western Regional Director of Sales
for Allergan Pharmaceuticals, where he directed and managed an 85
person sales division. Prior to this role, Mr. Ruth spent five
years in various Sales, Marketing and General Management roles for
Allergan. Previously, Mr. Ruth worked for a number of healthcare
related companies including Wilson Cook Medical, Inc. and Johnson
& Johnson Consumer Healthcare in progressively ascending levels
of responsibility. Mr. Ruth earned his Bachelor of Science degree
at Missouri State University in Springfield, MO. "Matt brings a
strong track record of success in sales management to Avanir," said
Keith Katkin, Senior Vice President, Sales & Marketing. "Matt's
general management experience as well as his recent experience
leading a sales force expansion at Allergan makes him the ideal
candidate to help Avanir become a leader in the field of
neurology." About AVANIR AVANIR Pharmaceuticals is focused on
developing and commercializing novel therapeutic products for the
treatment of chronic diseases. AVANIR's product candidates address
therapeutic markets that include central nervous system and
cardiovascular disorders, inflammation, and infectious diseases.
AVANIR previously announced positive results in the second of two
required Phase III clinical trials of Neurodex(TM), an
investigational new drug for the treatment of involuntary emotional
expression disorder (IEED). Additionally, AVANIR has initiated a
Phase III clinical trial for Neurodex as a potential treatment in
patients with diabetic neuropathic pain, a second indication for
Neurodex. AVANIR has active collaborations with two international
pharmaceutical companies: Novartis International Pharmaceutical
Ltd., for the treatment of inflammatory disease and AstraZeneca,
for the treatment of cardiovascular disease. The Company's first
commercialized product, "abreva(R)," is marketed in North America
by GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores. Further
information about AVANIR can be found at www.avanir.com.
Forward-Looking Statement The information contained in this press
release, including any forward-looking statements contained herein,
should be reviewed in conjunction with the Company's most recent
Annual Report on Form 10-K and quarterly report on Form 10-Q and
other publicly available information regarding the Company. Copies
of such information are available from the company upon request.
Such publicly available information sets forth many risks and
uncertainties related to the company's business and technology.
Forward-looking statements often contain such words like
"estimate," "anticipate," "believe," "plan" or "expect". Avanir
disclaims any intent or obligation to update these forward-looking
statements.
Avanir (AMEX:AVN.R)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Avanir (AMEX:AVN.R)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Avanir Pharmaceuticl (American Stock Exchange): 0 recent articles
Más de AVANIR Pharmaceuticals Artículos de Noticias